Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-23T09:01:17.477Z Has data issue: false hasContentIssue false
  • English
  • Français

Generic Substitution for Psychotropic Drugs

Published online by Cambridge University Press:  07 November 2014

Pierre Blier
Get access Rights & Permissions [Opens in a new window]

Extract

Most antidepressants and other psychotropics in clinical use are available as generic formulations (Table). The availability of lower-priced, generic drugs can benefit patients and third-party payers, but it should not be assumed that all generic drugs are equally beneficial. There are numerous reports in the literature of unexpected and untoward consequences that occur when a generic drug is substituted for the original brand-name drug. A previously stable clinical response may suddenly deteriorate, or the patient may experience new or more severe adverse events (AEs). The United States Food and Drug Administration requires that manufacturers of generic drugs demonstrate that their formulation has pharmacokinetic properties similar (or bioequivalent) to the brand-name drug. Bioequivalency studies are conducted in healthy volunteers, not in patients who would be treated with that drug. Moreover, bioequivalency studies are conducted on a current lot of the branded drug and do not account for variability between lots of the generic formulation. The manufacturer is only required to submit bioequivalency data that support the Abbreviated New Drug Application (ANDA); the FDA does not require disclosure of failed bioequivalence studies. Unlike brand-name drugs, lengthy and costly clinical studies are not required to show that the generic drug is effective and safe.

Although the FDA has taken the position that bioequivalence and therapeutic equivalence are equal, many questions related to the use of generic drugs remain unanswered. The following question-and-answer session is an excerpt of an interview with Pierre Blier, MD, PhD, conducted by Diane Sloan, PharmD, which addresses the issue of generic substitution of psychotropic drugs.

Type
Q&A Session
Information
CNS Spectrums , Volume 14 , Issue 9 , September 2009 , pp. 1 - 7
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Food and Drug Administration Electronic Orange Book. Approved Drug Products with Therapeutic Equivalence Evaluations. Available at: www.accessdata.fda.gov/scripts/cder/ob/default.cfm. Accessed September 10, 2009.Google Scholar
2.Genazzani, AA, Pattarino, F. Difficulties in the production of identical drug products from a pharmaceutical technology viewpoint. Drugs R D. 2008;9(2):65–72.Google Scholar
3.Borgheini, G. The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs. Clin Ther. 2003;25(6):1578–1592.Google Scholar
4.Kluznik, JC, Walbek, NH, Farnsworth, MG, Melstrom, K. Clinical effects of a randomized switch of patients from clozaril to generic clozapine. J Clin Psychiatry. 2001;62(suppl 5):14–17.Google Scholar
5.Privitera, MD. Generic antiepileptic drugs: current controversies and future directions. Epilepsy Curr. 2008;8(5):113–117.Google Scholar
6.Vergouwen, AC, Bakker, A. Adverse effects after switching to a different generic form of paroxetine: paroxetine mesylate instead of paroxetine HCI hemihydrate. Ned Tijdschr Geneeskd. 2002;146(17):811–812.Google Scholar
7.Alvarez, CA, Mascarenas, C, Timmerman, I. Increasing psychosis in a patient switched from clozaril to generic clozapine. Am J Psychiatry. 2006;163(4):746.Google Scholar
8.Van Ameringen, M, Mancini, C, Patterson, B, Bennett, M. Symptom relapse following switch from Celexa to generic citalopram: an anxiety disorders case series. J Psychopharmacol. 2007;21(5):472–476.Google Scholar
9.LeLorier, J, Duh, MS, Paradis, PE, et al.Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology. 2008;70(22 pt. 2):2179–2186.Google Scholar
10.Berg, MJ, Gross, RA, Tomaszewski, KJ, Zingaro, WM, Haskins, LS. Generic substitution in the treatment of epilepsy: case evidence of breakthrough seizures. Neurology. 2008;71(7):525–530.Google Scholar
11.Reiffel, JA, Kowey, PR. Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias. Am J Cordial. 2000;85(9):1151–1153, A10.Google Scholar
12.Rascati, KL, Richards, KM, Johnsrud, MT, Mann, TA. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy. 2009;29(7):769–774.Google Scholar
13.Duh, MS, Paradis, PE, Latrémouille-Viau, D, et al.The risks and costs of multiple-generic substitution of topiramate. Neurology. 2009;72(24):2122–2129.Google Scholar
14.Food and Drug Administration Office of Generic Drugs. Available at: www.fda.gov/AboutFDA/CentersOffices/CDER/ucml19100.htm. Accessed September 10, 2009.Google Scholar
15.Henney, JE. From the Food and Drug Administration. JAMA. 1999;282(21):1995.Google Scholar
16.Meyer, MC. United States Food and Drug Administration requirements for approval of generic drug products. J Clin Psychiatry. 2001;62(suppl 5):4–9.Google Scholar
17.United States Food and Drug Administration. Frequently asked questions on patents and exclusivity. Available at: www.fda.gov/Drugs/DevelopmentApprovalProcess/ucm079031.htm. Accessed September 10, 2009.Google Scholar
18.Druss, BG, Marcus, SC, Olfson, M, Pincus, HA. Listening to generic Prozac: winners, losers, and sideliners. Health Aff (Millwood). 2004;23(5):210–216.Google Scholar
19.Chen, Y, Kelton, CM, Jing, Y, Guo, JJ, Li, X, Patel, NC. Utilization, price, and spending trends for antidepressants in the US Medicaid program. Res Social Adm Pharm. 2008;4(3):244–257.Google Scholar
20.Food and Drug Administration. Bioavailability and Bioequivalence Requirements. Available at: www.access.gpo.gov/nara/cfr/waisidx_03/21cfr320_03.html. Accessed September 10, 2009.Google Scholar
21.Blier, P. Generic medications: another variable in the treatment of illnesses. J Psychopharmacol. 2007;21(5):459–460.Google Scholar
22.Nussbaum, AM, Stroup, TS. Paliperidone for treatment of schizophrenia. Schizophr Bull. 2008;34(3):419–422.Google Scholar
23.Gervasoni, M, Pirola, R, Bareggi, SR, Tonello, C, Nisoli, E, Vialba, L. The bioequivalence and therapeutic efficacy. Clin Ther. 2004;26(5):801–802.Google Scholar
24.Smith, JC, Tarocco, G, Merazzi, F, Salzmann, U. Are generic formulations of carvedilol of inferior pharmaceutical quality compared with the branded formulation? Curr Med Res Opin. 2006;22(4):709–720.Google Scholar
25.Swygert, LA, Back, EE, Auerbach, SB, Sewell, LE, Falk, H. Eosinophilia-myalgia syndrome: mortality data from the US national surveillance system. J Rheumatol. 1993;20(10):1711–1717.Google Scholar
26.Harris, G. US identifies tainted heparin in 11 countries. The New York Times. April 22, 2008. Available at: www.nytimes.com/2008/04/22/health/policy/22fda.html?_r=2. Accessed September 10, 2009.Google Scholar
27.American Epilepsy Society. The substitution of different formulations of antiepileptic drugs for the treatment of epilepsy. Available at: www.aesnet.org/index.cfm?objectid=77B10758-E7FF-OF412C82BE234AB8CD24. Accessed September 10, 2009.Google Scholar
28.Lam, YW, Ereshefsky, L, Toney, GB, Gonzales, C. Branded versus generic clozapine: bioavailability comparison and interchangeability issues. J Clin Psychiatry. 2001;62(suppl 5):18–22.Google Scholar
29.Chenu, F, Batten, L, Zernig, G, Ladstaetter, E, Hebert, C, Blier, P. Two generic antidepressant medications and their bioequivalence or bioinequivalence. Presented at: the Annual Meeting of the New Clinical Drug Evaluation Unit; June 29–July 2, 2009; Hollywood, FL. Abstract 341.Google Scholar